Tsuyoshi Okura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tsuyoshi Okura has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
Kazuhiro Yamamoto
National Cerebral and Cardiovascular Center Hospital Osaka Japan
19 shared publicationsMasahiko Kato
School of Health Science, Tottori University Faculty of Medicine, Yonago, Japan
17 shared publicationsShin-Ichi Taniguchi
Department of Community-Based Family Medicine, Faculty of Medicine, Tottori University, Yonago, JPN
17 shared publicationsKazuhiko Matsuzawa
Division of Multidisciplinary Internal Medicine, Department of Endocrinology and Metabolism, School of Medicine, Faculty of Medicine Tottori University Yonago Japan
15 shared publicationsRisa Nakamura
Division of Multidisciplinary Internal Medicine, Department of Endocrinology and Metabolism, School of Medicine, Faculty of Medicine Tottori University Yonago Japan
15 shared publicationsShoichiro Izawa
Department of Obstetrics and Gynecology, Faculty of Medicine, Tottori University, Yonago, JPN
15 shared publications
Latest Publications
- Open Access
- 4 September 2026
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 17 (11) , 2034-2043
Fasting serum annexin A2 is associated with peripheral insulin sensitivity and may enhance glucose uptake via Src‐dependent signaling
Background and Aim: Subcellular annexin A2 (ANXA2) is known to regulate membrane dynamics and GLUT4 trafficking in adipocytes; however, the role of serum ANXA2 in glucose metabolism remains unclear. We aimed to investigate the association between fasting serum ANXA2 and insulin sensitivity in humans and to examine the role of extracellular ANXA2 in glucose uptake in cultured skeletal myocytes. Methods: We conducted a clinical study in 15 non‐diabetic Japanese adults who underwent hyperinsulinemic–euglycemic glucose clamp studies to assess peripheral insulin sensitivity. Fasting serum ANXA2 levels were measured and correlated with metabolic parameters. Cultured C2C12 myotubes were treated with recombinant human ANXA2 and the effects of ANXA2 on glucose uptake and insulin signaling mediators were evaluated. Results: Fasting serum ANXA2 showed a significant positive correlation with mean glucose infusion rate (mean GIR; r = 0.76, P = 0.00095). In C2C12 myotubes, both ANXA2 and insulin significantly increased glucose uptake compared with controls. ANXA2 enhanced IRS‐1 and Akt phosphorylation independently of insulin, and this effect was suppressed by the Src‐kinase inhibitor PP2. Conclusions: In conclusion, these results indicated that fasting serum ANXA2 is associated with peripheral insulin sensitivity in humans, and that exogenous ANXA2 may enhance glucose uptake in association with IRS‐1/Akt signaling and Src‐dependent pathways. Together, these findings support further evaluation of serum ANXA2 as a potential indicator reflecting peripheral insulin sensitivity.
- 4 September 2026
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 17 (11) , 2034-2043
Open AccessFasting serum annexin A2 is associated with peripheral insulin sensitivity and may enhance glucose uptake via Src‐dependent signaling
Background and Aim: Subcellular annexin A2 (ANXA2) is known to regulate membrane dynamics and GLUT4 trafficking in adipocytes; however, the role of serum ANXA2 in glucose metabolism remains unclear. We aimed to investigate the association between fasting serum ANXA2 and insulin sensitivity in humans and to examine the role of extracellular ANXA2 in glucose uptake in cultured skeletal myocytes. Methods: We conducted a clinical study in 15 non‐diabetic Japanese adults who underwent hyperinsulinemic–euglycemic glucose clamp studies to assess peripheral insulin sensitivity. Fasting serum ANXA2 levels were measured and correlated with metabolic parameters. Cultured C2C12 myotubes were treated with recombinant human ANXA2 and the effects of ANXA2 on glucose uptake and insulin signaling mediators were evaluated. Results: Fasting serum ANXA2 showed a significant positive correlation with mean glucose infusion rate (mean GIR; r = 0.76, P = 0.00095). In C2C12 myotubes, both ANXA2 and insulin significantly increased glucose uptake compared with controls. ANXA2 enhanced IRS‐1 and Akt phosphorylation independently of insulin, and this effect was suppressed by the Src‐kinase inhibitor PP2. Conclusions: In conclusion, these results indicated that fasting serum ANXA2 is associated with peripheral insulin sensitivity in humans, and that exogenous ANXA2 may enhance glucose uptake in association with IRS‐1/Akt signaling and Src‐dependent pathways. Together, these findings support further evaluation of serum ANXA2 as a potential indicator reflecting peripheral insulin sensitivity.
- 23 January 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (4) , 3020-3032
Methylglyoxal‐derived hydroimidazolone ( MG ‐ H1 ) is a novel marker of insulin resistance in Japanese individuals, disturbing insulin signalling via mTORC2 in cultured myocytes
Background and Aims: Methylglyoxal‐derived hydroimidazolone (MG‐H1), one of the advanced glycation end‐products (AGEs), has been a potential biomarker of type 2 diabetes (T2DM), which is strongly related to insulin resistance. However, the relationship between the dynamics of MG‐H1 and insulin resistance has not been characterized, and its mechanism on insulin resistance is unknown. In this study, we aimed to investigate the relationship between MG‐H1 and insulin resistance in the clinical study of Japanese individuals and identify the molecular mechanisms underlying MG‐H1 associated phenomena in vitro. Methods: We performed the meal tolerance test (MTT) and hyper‐insulinemic–euglycemic clamp analysis in 19 patients with T2DM and 19 participants without diabetes (non‐DM). We measured their fasting and postprandial MG‐H1 using liquid chromatography–tandem mass spectrometry (LC–MS/MS). In addition, we evaluated the effects of MG‐H1 on glucose uptake and insulin signalling in C2C12 skeletal myocytes. Results: The postprandial MG‐H1 and the area under the curve (AUC) of MG‐H1 in MTTs were significantly negatively correlated with the glucose disposal rate (GDR) in clamp studies both in the T2DM ( r = −0.72 [ p < 0.001]) and non‐DM ( r = −0.54 [ p < 0.05]) groups. In cultured C2C12 skeletal myocytes, pre‐treatment with MG‐H1 inhibited insulin‐stimulated phosphorylation of Akt and glucose uptake, via the activation of mechanistic target of rapamycin complex 2 (mTORC2). Conclusions: In clinical study findings revealed that postprandial MG‐H1 was a novel marker of insulin resistance in Japanese individuals, and in vitro findings using cultured C2C12 skeletal myocytes suggested that MG‐H1 disturbs insulin signalling via the mechanisms of mTORC2 activation.
- 23 January 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (4) , 3020-3032
Methylglyoxal‐derived hydroimidazolone ( MG ‐ H1 ) is a novel marker of insulin resistance in Japanese individuals, disturbing insulin signalling via mTORC2 in cultured myocytes
Background and Aims: Methylglyoxal‐derived hydroimidazolone (MG‐H1), one of the advanced glycation end‐products (AGEs), has been a potential biomarker of type 2 diabetes (T2DM), which is strongly related to insulin resistance. However, the relationship between the dynamics of MG‐H1 and insulin resistance has not been characterized, and its mechanism on insulin resistance is unknown. In this study, we aimed to investigate the relationship between MG‐H1 and insulin resistance in the clinical study of Japanese individuals and identify the molecular mechanisms underlying MG‐H1 associated phenomena in vitro. Methods: We performed the meal tolerance test (MTT) and hyper‐insulinemic–euglycemic clamp analysis in 19 patients with T2DM and 19 participants without diabetes (non‐DM). We measured their fasting and postprandial MG‐H1 using liquid chromatography–tandem mass spectrometry (LC–MS/MS). In addition, we evaluated the effects of MG‐H1 on glucose uptake and insulin signalling in C2C12 skeletal myocytes. Results: The postprandial MG‐H1 and the area under the curve (AUC) of MG‐H1 in MTTs were significantly negatively correlated with the glucose disposal rate (GDR) in clamp studies both in the T2DM ( r = −0.72 [ p < 0.001]) and non‐DM ( r = −0.54 [ p < 0.05]) groups. In cultured C2C12 skeletal myocytes, pre‐treatment with MG‐H1 inhibited insulin‐stimulated phosphorylation of Akt and glucose uptake, via the activation of mechanistic target of rapamycin complex 2 (mTORC2). Conclusions: In clinical study findings revealed that postprandial MG‐H1 was a novel marker of insulin resistance in Japanese individuals, and in vitro findings using cultured C2C12 skeletal myocytes suggested that MG‐H1 disturbs insulin signalling via the mechanisms of mTORC2 activation.
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Endocrinology
- Vol. 2026 (1) , 9463565
A Rare Case of Bartter Syndrome Type 3 Diagnosed in Elderly Age
Bartter syndrome (BS) type 3 typically presents in childhood and is caused by defects in NaCl transporters of the thick ascending limb of the loop of Henle. We report a 66‐year‐old woman with asymptomatic but severe hypokalemia (2.0 mmol/L), metabolic alkalosis, and hyperreninemic hyperaldosteronism. Initial clinic blood pressure was 157/88 mmHg, but repeated office and home measurements were ~120/70 mmHg, consistent with white‐coat hypertension. Imaging excluded renovascular disease. Sequential diuretic testing supported BS physiology: a thiazide loading test increased fractional excretion of chloride (FECl) from 0.46% to 3.88% (ΔFECl 3.4%), exceeding the 2.3% cutoff that argues against Gitelman syndrome; a furosemide test showed chloride reabsorption of 10.1%, indicating a profound loop‐segment defect, even lower than values commonly reported in BS3. Targeted next‐generation sequencing identified a homozygous CLCNKB stop‐gain variant (c.1830G >A; p.Trp610Ter), confirming BS type 3. High‐dose potassium chloride (9.9 g/day) failed to correct hypokalemia, whereas low‐dose enalapril plus spironolactone normalized serum potassium (4.0 mmol/L) without persistent hypotension. The urine calcium/creatinine ratio was borderline‐normal (0.65 mmol/mmol), rather than hypocalciuric. This case suggests that BS3 should remain in the differential diagnosis of refractory hypokalemia in older adults and highlights the diagnostic value of physiology‐guided diuretic testing combined with genetic analysis, as well as the potential efficacy of low‐dose ACE inhibitor plus mineralocorticoid receptor antagonist therapy when potassium supplementation alone is insufficient.
- 1 January 2026
- Published by Wiley in Case Reports in Endocrinology
- Vol. 2026 (1) , 9463565
Open AccessA Rare Case of Bartter Syndrome Type 3 Diagnosed in Elderly Age
Bartter syndrome (BS) type 3 typically presents in childhood and is caused by defects in NaCl transporters of the thick ascending limb of the loop of Henle. We report a 66‐year‐old woman with asymptomatic but severe hypokalemia (2.0 mmol/L), metabolic alkalosis, and hyperreninemic hyperaldosteronism. Initial clinic blood pressure was 157/88 mmHg, but repeated office and home measurements were ~120/70 mmHg, consistent with white‐coat hypertension. Imaging excluded renovascular disease. Sequential diuretic testing supported BS physiology: a thiazide loading test increased fractional excretion of chloride (FECl) from 0.46% to 3.88% (ΔFECl 3.4%), exceeding the 2.3% cutoff that argues against Gitelman syndrome; a furosemide test showed chloride reabsorption of 10.1%, indicating a profound loop‐segment defect, even lower than values commonly reported in BS3. Targeted next‐generation sequencing identified a homozygous CLCNKB stop‐gain variant (c.1830G >A; p.Trp610Ter), confirming BS type 3. High‐dose potassium chloride (9.9 g/day) failed to correct hypokalemia, whereas low‐dose enalapril plus spironolactone normalized serum potassium (4.0 mmol/L) without persistent hypotension. The urine calcium/creatinine ratio was borderline‐normal (0.65 mmol/mmol), rather than hypocalciuric. This case suggests that BS3 should remain in the differential diagnosis of refractory hypokalemia in older adults and highlights the diagnostic value of physiology‐guided diuretic testing combined with genetic analysis, as well as the potential efficacy of low‐dose ACE inhibitor plus mineralocorticoid receptor antagonist therapy when potassium supplementation alone is insufficient.
- Open Access
- 12 December 2024
- Published by Springer Nature in Cureus
- Vol. 16 (12) , e75612
Pregestational BMI Over 23 kg/m2 May Increase Insulin Utilization in Gestational Diabetes Mellitus Patients
The purpose of this study is to examine the pregestational BMI value that results in insulin use in Japanese patients with gestational diabetes mellitus (GDM) and to assess whether the type of GDM treatment affects postpartum glucose tolerance. This retrospective study included 21 GDM patients treated until parturition at our department from 2013 to 2017. We calculated the pregestational BMI related to insulin treatment and the significant elevation in homeostasis model assessment of insulin resistance (HOMA-IR) by receiver operating characteristics curve (ROC) analysis. We also analyzed whether the insulin treatment caused a difference in postpartum glucose tolerance. Seven of the eight patients who needed insulin treatment had a pregestational BMI over 23 kg/m2. The pregestational BMI cutoff value related to insulin treatment was 22.5 kg/m2 (sensitivity 100%, specificity 46.2%, area under the curve 0.668, and Confidence Interval=0.429-0.907) in ROC analysis. Insulin utilization was significantly higher in the group with a pregestational BMI of 22.5 or more (p=0.045). HOMA-IR at postpartum was higher in patients whose pregestational BMI was 22.5kg/m2 or more. Blood glucose levels, HOMA-IR, homeostasis model assessment of β-cell function (HOMA-β), and the insulinogenic index (IGI) after delivery did not differ between the diet and insulin treatment groups. In conclusion, Japanese women with GDM and a pregestational BMI over 23 kg/m2 may increase the risk of requiring insulin treatment during pregnancy. Postpartum glucose tolerance did not differ between patients treated with diet or insulin treatment for GDM.
- 12 December 2024
- Published by Springer Nature in Cureus
- Vol. 16 (12) , e75612
Open AccessPregestational BMI Over 23 kg/m2 May Increase Insulin Utilization in Gestational Diabetes Mellitus Patients
The purpose of this study is to examine the pregestational BMI value that results in insulin use in Japanese patients with gestational diabetes mellitus (GDM) and to assess whether the type of GDM treatment affects postpartum glucose tolerance. This retrospective study included 21 GDM patients treated until parturition at our department from 2013 to 2017. We calculated the pregestational BMI related to insulin treatment and the significant elevation in homeostasis model assessment of insulin resistance (HOMA-IR) by receiver operating characteristics curve (ROC) analysis. We also analyzed whether the insulin treatment caused a difference in postpartum glucose tolerance. Seven of the eight patients who needed insulin treatment had a pregestational BMI over 23 kg/m2. The pregestational BMI cutoff value related to insulin treatment was 22.5 kg/m2 (sensitivity 100%, specificity 46.2%, area under the curve 0.668, and Confidence Interval=0.429-0.907) in ROC analysis. Insulin utilization was significantly higher in the group with a pregestational BMI of 22.5 or more (p=0.045). HOMA-IR at postpartum was higher in patients whose pregestational BMI was 22.5kg/m2 or more. Blood glucose levels, HOMA-IR, homeostasis model assessment of β-cell function (HOMA-β), and the insulinogenic index (IGI) after delivery did not differ between the diet and insulin treatment groups. In conclusion, Japanese women with GDM and a pregestational BMI over 23 kg/m2 may increase the risk of requiring insulin treatment during pregnancy. Postpartum glucose tolerance did not differ between patients treated with diet or insulin treatment for GDM.
- Open Access
- 5 December 2024
- Published by Springer Nature in Hypertension Research
- Vol. 48 (3) , 1218-1220
The importance of the time in target range (TTR) of glucose and blood pressure
- 5 December 2024
- Published by Springer Nature in Hypertension Research
- Vol. 48 (3) , 1218-1220
Open AccessThe importance of the time in target range (TTR) of glucose and blood pressure
- 26 July 2024
- Published by Springer Nature in Diabetologia
- Vol. 67 (10) , 2304-2315
Postprandial fatty acid-binding protein 4 is associated with muscle insulin resistance
Aims/hypothesis Fatty acid-binding protein 4 (FABP4) has been reported to act as a hepatic insulin resistance factor. We previously reported that fasting FABP4 was correlated with insulin resistance measurements derived from the glucose clamp, and another study reported that postprandial FABP4 levels were decreased in healthy volunteers but were not reported (or known) in participants with type 2 diabetes. We have limited knowledge about the direct effect of FABP4 on muscle cells. We investigated the postprandial FABP4 levels in participants with type 2 diabetes, and the basic mechanism of muscle insulin resistance and FABP4. Methods We performed a meal tolerance test and hyperinsulinaemic–euglycaemic clamp in 22 participants with type 2 diabetes and 26 participants without diabetes. We measured fasting and postprandial serum FABP4. We cultured mouse C2C12 muscle cells, and investigated the effect of FABP4 on glucose uptake. We analysed insulin signalling by western blot and insulin binding assay. Results The postprandial FABP4 level in participants with type 2 diabetes was higher than that in participants without diabetes. Participants without diabetes had lower postprandial FABP4 than fasting except for one participant, whereas one-third of participants with type 2 diabetes had higher postprandial FABP4 than fasting. Postprandial FABP4 was correlated with the muscle insulin resistance M/I value from a glucose clamp in participants without diabetes (r=−0.42, pM/I value (r=−0.44, pr=0.36, p<0.05). FABP4 alone appears to increase glucose uptake, and the combination of FABP4 and insulin decreases glucose uptake when compared with insulin alone. FABP4 inhibits insulin signalling of muscle cells through decreases in phosphorylation of insulin receptor substrate 1 and Akt. The physiological concentration of FABP4 did not inhibit insulin binding to muscle cells. Conclusions/interpretation These results suggested that the postprandial FABP4 level is associated with insulin resistance, and FABP4 may suppress insulin signals. Graphical Abstract
- 26 July 2024
- Published by Springer Nature in Diabetologia
- Vol. 67 (10) , 2304-2315
Postprandial fatty acid-binding protein 4 is associated with muscle insulin resistance
Aims/hypothesis Fatty acid-binding protein 4 (FABP4) has been reported to act as a hepatic insulin resistance factor. We previously reported that fasting FABP4 was correlated with insulin resistance measurements derived from the glucose clamp, and another study reported that postprandial FABP4 levels were decreased in healthy volunteers but were not reported (or known) in participants with type 2 diabetes. We have limited knowledge about the direct effect of FABP4 on muscle cells. We investigated the postprandial FABP4 levels in participants with type 2 diabetes, and the basic mechanism of muscle insulin resistance and FABP4. Methods We performed a meal tolerance test and hyperinsulinaemic–euglycaemic clamp in 22 participants with type 2 diabetes and 26 participants without diabetes. We measured fasting and postprandial serum FABP4. We cultured mouse C2C12 muscle cells, and investigated the effect of FABP4 on glucose uptake. We analysed insulin signalling by western blot and insulin binding assay. Results The postprandial FABP4 level in participants with type 2 diabetes was higher than that in participants without diabetes. Participants without diabetes had lower postprandial FABP4 than fasting except for one participant, whereas one-third of participants with type 2 diabetes had higher postprandial FABP4 than fasting. Postprandial FABP4 was correlated with the muscle insulin resistance M/I value from a glucose clamp in participants without diabetes (r=−0.42, pM/I value (r=−0.44, pr=0.36, p<0.05). FABP4 alone appears to increase glucose uptake, and the combination of FABP4 and insulin decreases glucose uptake when compared with insulin alone. FABP4 inhibits insulin signalling of muscle cells through decreases in phosphorylation of insulin receptor substrate 1 and Akt. The physiological concentration of FABP4 did not inhibit insulin binding to muscle cells. Conclusions/interpretation These results suggested that the postprandial FABP4 level is associated with insulin resistance, and FABP4 may suppress insulin signals. Graphical Abstract
- Open Access
- 20 December 2023
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 15 (1) , 1-8
Fasting hepatic insulin clearance reflects postprandial hepatic insulin clearance: a brief report
Background: Hepatic insulin clearance (HIC) is an important pathophysiology of type 2 diabetes mellitus (T2DM). HIC was reported to decrease in patients with type 2 diabetes and metabolic syndrome. HIC is originally calculated by post-load insulin and C-peptide from the oral glucose tolerance test (OGTT). However, OGTT or meal tolerance tests are a burden for patients, and OGTT is not suitable for overt diabetes due to the risk of hyperglycemia. If we can calculate the HIC from the fasting state, it is preferable. We hypothesized that fasting HIC correlates with postprandial HIC in both participants with T2DM and without diabetes. We investigated whether fasting HIC correlates with postprandial HIC in overt T2DM and nondiabetes subjects (non-DM) evaluated by using glucose clamp and meal load. Methods: We performed a meal tolerance test and hyperinsulinemic–euglycemic clamp in 70 subjects, 31 patients with T2DM and 39 non-DM subjects. We calculated the postprandial C-peptide AUC-to-insulin AUC ratio as the postprandial HIC and the fasting C-peptide-to-insulin ratio as the fasting HIC. We also calculated whole-body insulin clearance from the glucose clamp test. Results: The fasting HIC significantly correlated with postprandial HIC in T2DM (r_S = 0.82, P < 0.001). Nondiabetes subjects also showed a significant correlation between fasting and postprandial HIC (r_S = 0.71, P < 0.001). Fasting HIC in T2DM was correlated with BMI, HbA1c, gamma-glutamyl transpeptidase, HOMA-IR, HOMA-beta, M/I, and whole-body insulin clearance. Fasting HIC in nondiabetes subjects was correlated with HOMA-IR and HOMA-beta. Conclusions: These results suggest that fasting HIC is strongly correlated with postprandial HIC in both overt T2DM and non-DM patients, as evaluated by the meal test and glucose clamp method. Fasting HIC could be a convenient marker of HIC.
- 20 December 2023
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 15 (1) , 1-8
Open AccessFasting hepatic insulin clearance reflects postprandial hepatic insulin clearance: a brief report
Background: Hepatic insulin clearance (HIC) is an important pathophysiology of type 2 diabetes mellitus (T2DM). HIC was reported to decrease in patients with type 2 diabetes and metabolic syndrome. HIC is originally calculated by post-load insulin and C-peptide from the oral glucose tolerance test (OGTT). However, OGTT or meal tolerance tests are a burden for patients, and OGTT is not suitable for overt diabetes due to the risk of hyperglycemia. If we can calculate the HIC from the fasting state, it is preferable. We hypothesized that fasting HIC correlates with postprandial HIC in both participants with T2DM and without diabetes. We investigated whether fasting HIC correlates with postprandial HIC in overt T2DM and nondiabetes subjects (non-DM) evaluated by using glucose clamp and meal load. Methods: We performed a meal tolerance test and hyperinsulinemic–euglycemic clamp in 70 subjects, 31 patients with T2DM and 39 non-DM subjects. We calculated the postprandial C-peptide AUC-to-insulin AUC ratio as the postprandial HIC and the fasting C-peptide-to-insulin ratio as the fasting HIC. We also calculated whole-body insulin clearance from the glucose clamp test. Results: The fasting HIC significantly correlated with postprandial HIC in T2DM (r_S = 0.82, P < 0.001). Nondiabetes subjects also showed a significant correlation between fasting and postprandial HIC (r_S = 0.71, P < 0.001). Fasting HIC in T2DM was correlated with BMI, HbA1c, gamma-glutamyl transpeptidase, HOMA-IR, HOMA-beta, M/I, and whole-body insulin clearance. Fasting HIC in nondiabetes subjects was correlated with HOMA-IR and HOMA-beta. Conclusions: These results suggest that fasting HIC is strongly correlated with postprandial HIC in both overt T2DM and non-DM patients, as evaluated by the meal test and glucose clamp method. Fasting HIC could be a convenient marker of HIC.
- Open Access
- 10 April 2023
- Published by Elsevier in Metabolism Open
- Vol. 18, 100242
Aldehyde dehydrogenase 2 polymorphism is an important gene for insulin resistance in Japanese patients with type 2 diabetes
- 10 April 2023
- Published by Elsevier in Metabolism Open
- Vol. 18, 100242
Open AccessAldehyde dehydrogenase 2 polymorphism is an important gene for insulin resistance in Japanese patients with type 2 diabetes
- Open Access
- 8 September 2022
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 10 (5) , e002908
Significance of pancreatic duodenal homeobox-1 (PDX-1) genetic polymorphism in insulin secretion in Japanese patients with type 2 diabetes
Introduction: Pancreatic and duodenal homeobox factor-1 (PDX-1) is an imperative gene for insulin secretion in maturity-onset diabetes of the young 4. PDX-1 gene polymorphism was associated with lower first-phase insulin secretion in a genome-wide association study of intravenous glucose tolerance test. It was not associated with type 2 diabetes risk and insulin secretion in a genome-wide oral glucose tolerance test study. However, there have been no reports of overt type 2 diabetes and insulin resistance evaluation using a glucose clamp. We investigated PDX-1 polymorphism, insulin secretion, and insulin resistance in overt type 2 diabetes. Research design and methods: We performed a meal tolerance test (MTT) and hyperinsulinemic–euglycemic clamping on 63 Japanese subjects, 30 with type 2 diabetes and 33 non-diabetic. We analyzed the rs1124607 PDX-1 gene polymorphism and defined A/C and C/C as the high-risk group and A/A as the low-risk group. Results: HOMA-beta (homeostatic model assessment beta-cell function) was significantly lower in the high-risk group than in the low-risk group for all subjects (72.9±54.2% vs 107.0±63.5%, pPDX-1 genetic polymorphism is crucial for insulin secretion in Japanese patients with type 2 diabetes.
- 8 September 2022
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 10 (5) , e002908
Open AccessSignificance of pancreatic duodenal homeobox-1 (PDX-1) genetic polymorphism in insulin secretion in Japanese patients with type 2 diabetes
Introduction: Pancreatic and duodenal homeobox factor-1 (PDX-1) is an imperative gene for insulin secretion in maturity-onset diabetes of the young 4. PDX-1 gene polymorphism was associated with lower first-phase insulin secretion in a genome-wide association study of intravenous glucose tolerance test. It was not associated with type 2 diabetes risk and insulin secretion in a genome-wide oral glucose tolerance test study. However, there have been no reports of overt type 2 diabetes and insulin resistance evaluation using a glucose clamp. We investigated PDX-1 polymorphism, insulin secretion, and insulin resistance in overt type 2 diabetes. Research design and methods: We performed a meal tolerance test (MTT) and hyperinsulinemic–euglycemic clamping on 63 Japanese subjects, 30 with type 2 diabetes and 33 non-diabetic. We analyzed the rs1124607 PDX-1 gene polymorphism and defined A/C and C/C as the high-risk group and A/A as the low-risk group. Results: HOMA-beta (homeostatic model assessment beta-cell function) was significantly lower in the high-risk group than in the low-risk group for all subjects (72.9±54.2% vs 107.0±63.5%, pPDX-1 genetic polymorphism is crucial for insulin secretion in Japanese patients with type 2 diabetes.
- Open Access
- 7 June 2022
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 14 (1) , 1-6
Dipeptidyl peptidase 4 inhibitor improves insulin resistance in Japanese patients with type 2 diabetes: a single-arm study, a brief report
Background: Dipeptidyl peptidase 4 inhibitor (DPP4i) is an effective medicine for type 2 diabetes mellitus (T2DM). Some articles reported DPP4i improves insulin secretion and insulin resistance. However, these effects are not well established by glucose clamp test and test meal in Japanese. We investigated the effect of DPP4i on insulin resistance and insulin secretion by using the glucose clamp test and meal tolerance test (MTT). Methods: We performed a MTT, and the hyperinsulinemic-euglycemic clamp in 8 Japanese patients with T2DM. This study was a single-arm study. We measured fasting and postprandial glucose, insulin, incretins, and glucagon levels. We also measured serum adiponectin levels. Results: HbA1c was significantly decreased after 3 months. The fasting and postprandial glucose levels were significantly decreased. Fasting and postprandial insulin levels were not changed. The insulin resistance derived from the glucose clamp test was significantly improved. HOMA-IR was not significantly changed. GLP-1 and GIP were significantly increased but glucagon did not change. Adiponectin was not significantly changed. Conclusions: Although the number of patients was very small, these results suggested that DPP4i treatment might improve insulin resistance without changing insulin secretion.
- 7 June 2022
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 14 (1) , 1-6
Open AccessDipeptidyl peptidase 4 inhibitor improves insulin resistance in Japanese patients with type 2 diabetes: a single-arm study, a brief report
Background: Dipeptidyl peptidase 4 inhibitor (DPP4i) is an effective medicine for type 2 diabetes mellitus (T2DM). Some articles reported DPP4i improves insulin secretion and insulin resistance. However, these effects are not well established by glucose clamp test and test meal in Japanese. We investigated the effect of DPP4i on insulin resistance and insulin secretion by using the glucose clamp test and meal tolerance test (MTT). Methods: We performed a MTT, and the hyperinsulinemic-euglycemic clamp in 8 Japanese patients with T2DM. This study was a single-arm study. We measured fasting and postprandial glucose, insulin, incretins, and glucagon levels. We also measured serum adiponectin levels. Results: HbA1c was significantly decreased after 3 months. The fasting and postprandial glucose levels were significantly decreased. Fasting and postprandial insulin levels were not changed. The insulin resistance derived from the glucose clamp test was significantly improved. HOMA-IR was not significantly changed. GLP-1 and GIP were significantly increased but glucagon did not change. Adiponectin was not significantly changed. Conclusions: Although the number of patients was very small, these results suggested that DPP4i treatment might improve insulin resistance without changing insulin secretion.